OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Levy on the Future of Atezolizumab in NSCLC

November 11th 2022

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

November 11th 2022

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC

November 11th 2022

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

Dr. Shore on the Importance of Genetic Testing in Prostate Cancer

November 11th 2022

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma

November 11th 2022

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

Dr. Kim on The Evaluation of TKI/Immunotherapy Combos in HCC

November 11th 2022

Richard Kim, MD, discusses the evaluation of TKI and immunotherapy combination regimens in hepatocellular carcinoma.

Dr. Halmos on the FDA Approval of Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

November 11th 2022

Balazs Halmos, MD, discusses the significance of the FDA approval of tremelimumab-actl plus durvalumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Perl on Genetic Testing and Targeted Therapies in AML

November 10th 2022

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Dr. Kris on Atezolizumab in NSCLC

November 10th 2022

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

Dr. Rugo on HER2 Differentiation in Metastatic Breast Cancer

November 9th 2022

Hope Rugo, MD, discusses the challenges of differentiating between HER2-low and HER2-negative metastatic breast cancer and prognostic differences in HER2+ and HER2-low metastatic breast cancer.

Dr. Klempner on the Significance of KRYSTAL-1 Data in KRAS G12C–Mutant CRC

November 9th 2022

Sam Klempner, MD, discusses the incidence of KRAS G12C mutations in patients with metastatic colorectal cancer, the viability of the target in this disease, the efficacy of adagrasib in combination with cetuximab in this patient population, and the importance of genetic testing.

Dr. Awan on Selecting BTK Inhibitors for CLL Management

November 7th 2022

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC

November 7th 2022

Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

November 4th 2022

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Dr. McKay on Tivozanib Plus Nivolumab in Advanced RCC

November 4th 2022

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

Dr. McGregor on Belzutifan Plus Lenvatinib in Advanced RCC

November 4th 2022

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

Dr. Jonasch on the Exploration of Cabozantinib in the Neoadjuvant Setting in RCC

November 4th 2022

Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.

Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric Cancer

November 4th 2022

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

Dr. Epstein-Peterson on the Importance of Treatment Sequencing Decisions in MCL

November 4th 2022

Zachary Epstein-Peterson, MD, discusses the importance of treatment sequencing decisions in mantle cell lymphoma.